Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Droshatm1Ghan mutation
(0 available);
any
Drosha mutation
(96 available)
Tg(KRT5-rtTA)1Glk mutation
(0 available)
Tg(tetO-cre)1Jaw mutation
(5 available)
|
|
|
integument
|
|
• at P50 doxycycline-treated mice exhibit loss of bulge stem cells unlike in control mice
• however, bulge stem cells are present at P20 and P22
|
growth/size/body
|
|
• in doxycycline-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Droshatm1Litt mutation
(1 available);
any
Drosha mutation
(96 available)
Tg(KRT5-rtTA)1Glk mutation
(0 available)
Tg(tetO-cre)1Jaw mutation
(5 available)
|
|
|
integument
|
N |
• doxycycline-treated mice retain hair follicle stem cells in early telogen and anagen
|
|
|
• hair phenotype in doxycycline-treated mice appears more slowly than in Dicer1tm1Smr/Dicer1tm1Smr Tg(KRT5-rtTA)1Glk Tg(tetO-cre)1Jaw mice
|
|
|
• failure of hair regrowth in doxycycline-treated mice
• failure of regression at P20 in doxycycline-treated mice and remained in an abnormal growth phase
• following hair plucking, doxycycline-treated mice fail to sustain hair growth unlike control mice
|
|
|
• after P14 in doxycycline-treated mice
|
|
|
• external hair becomes wavy between P12 and P14 in doxycycline-treated mice
|
|
|
• in doxycycline-treated mice likely due to matrix cell apoptosis
|
|
|
• at P17 in doxycycline-treated mice after degradation begins
|
|
|
• fewer differentiation cell in doxycycline-treated mice following plucking-induced anagen initiation
|
|
|
• with extrusion of abnormally keratinized cellular material in doxycycline-treated mice
|
|
|
• in doxycycline-treated mice following plucking-induced anagen initiation
|
|
|
• failure of catagen in doxycycline-treated mice
|
|
|
• failure of regression at P20 in doxycycline-treated mice
|
|
|
• by P20, doxycycline-treated mice exhibit thickened interfollicular epidermis compared with control mice
|
|
|
• mice treated with doxycycline exhibit a temporary phenotype of dry scaly skin that is resolved in an anterior-posterior direction
|
|
|
• mice treated with doxycycline exhibit a temporary phenotype of dry scaly skin that is resolved in an anterior-posterior direction
|
cellular
|
|
• doxycycline-treated mice exhibit matrix cell apoptosis with DNA damage response unlike in control mice
|
growth/size/body
|
|
• in doxycycline-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dicer1tm1Smr mutation
(1 available);
any
Dicer1 mutation
(94 available)
Tg(KRT5-rtTA)1Glk mutation
(0 available)
Tg(tetO-cre)1Jaw mutation
(5 available)
|
|
|
integument
|
N |
• doxycycline-treated mice retain hair follicle stem cells in early telogen and anagen
|
|
|
• hair phenotype in doxycycline-treated mice appears more rapidly than in Droshatm1Litt/Droshatm1Litt Tg(KRT5-rtTA)1Glk Tg(tetO-cre)1Jaw mice
|
|
|
• failure of hair regrowth in doxycycline-treated mice
• failure of regression at P20 in doxycycline-treated mice and remained in an abnormal growth phase
• following hair plucking, doxycycline-treated mice fail to sustain hair growth unlike control mice
|
|
|
• after P14 in doxycycline-treated mice
|
|
|
• external hair becomes wavy between P12 and P14 in doxycycline-treated mice
|
|
|
• in doxycycline-treated mice likely due to matrix cell apoptosis
|
|
|
• at P17 in doxycycline-treated mice after degradation begins
|
|
|
• fewer differentiation cell in doxycycline-treated mice following plucking-induced anagen initiation
|
|
|
• at P59 doxycycline-treated mice exhibit loss of bulge stem cells unlike in control mice
• however, bulge stem cells are present at P20 and P22
|
|
|
• with extrusion of abnormally keratinized cellular material in doxycycline-treated mice
|
|
|
• in doxycycline-treated mice following plucking-induced anagen initiation
|
|
|
• failure of catagen in doxycycline-treated mice
|
|
|
• failure of regression at P20 in doxycycline-treated mice
|
|
|
• by P20, doxycycline-treated mice exhibit thickened interfollicular epidermis compared with control mice
|
|
|
• mice treated with doxycycline exhibit a temporary phenotype of dry scaly skin that is resolved in an anterior-posterior direction
|
|
|
• mice treated with doxycycline exhibit a temporary phenotype of dry scaly skin that is resolved in an anterior-posterior direction
|
cellular
|
|
• doxycycline-treated mice exhibit matrix cell apoptosis with DNA damage response unlike in control mice
|
growth/size/body
|
|
• in doxycycline-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
immune system
|
|
• dox treated mutants develop autoimmune hemolytic anemia
|
|
|
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses
|
|
|
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential
|
|
|
• dox treated mutants exhibit an increase in serum IL-4 levels
|
|
|
• following dox treatment, mutants show the presence of anti-RBC-specific autoantibodies
|
hematopoietic system
|
|
• dox treated mutants develop autoimmune hemolytic anemia
|
|
|
• following dox treatment, mutants show a decrease in hematocrit corresponding with the presence of anti-RBC-specific autoantibodies, consistent with onset of hemolytic anemia
|
|
|
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses
|
|
|
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential
|
homeostasis/metabolism
cellular
|
|
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tcrbtm1Mom mutation
(12 available);
any
Tcrb mutation
(94 available)
Tg(KRT5-rtTA)1Glk mutation
(0 available)
Tg(tetO/CMV-Tslp)#Sfz mutation
(0 available)
|
|
|
integument
|
|
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils
|
|
|
• mutants treated with doxycycline (dox) for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils
|
|
|
• mutants treated with dox for 3 weeks exhibit epidermal thickening
|
immune system
|
|
• dox treated mice exhibit little or no serum IgE
|
|
|
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils
|
hematopoietic system
|
|
• dox treated mice exhibit little or no serum IgE
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
integument
|
|
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis
|
|
|
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• however, inflammation is not seen in the small intestine or colon
|
|
|
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis
|
|
|
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis
|
|
|
• majority of dox treated mice exhibit a mild xerosis
|
|
|
• seen in dox treated mutants
|
|
|
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back
• less commonly, lesions are seen on the anterior neck and hind legs
|
immune system
|
|
• dox treated mutants exhibit splenomegaly
|
|
|
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
|
|
|
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin
|
|
|
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes
|
|
|
• dox treated mutants exhibit lymphadenopathy
|
|
|
• a few dox treated mice exhibit conjunctivitis
|
|
|
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils
• however, inflammation is not seen in the small intestine or colon
|
hematopoietic system
|
|
• dox treated mutants exhibit splenomegaly
|
|
|
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes
|
homeostasis/metabolism
vision/eye
|
|
• a few dox treated mice exhibit conjunctivitis
|
growth/size/body
|
|
• dox treated mutants exhibit splenomegaly
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
immune system
|
|
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice
|
|
|
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin
|
|
|
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice
|
integument
|
|
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice
|
respiratory system
|
|
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin
|
hematopoietic system
|
|
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice
|
cellular
|
|
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
immune system
|
N |
• doxycycline- and anti-mTSLP antibody-treated mice do not exhibit eczematous inflammation
|
integument
|
N |
• doxycycline- and anti-mTSLP antibody-treated mice do not exhibit eczematous inflammation
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
mortality/aging
|
N |
• double-transgenic mice with normal morphology are born at expected ratios when no doxycycline treatment is given to the dam
|
immune system
|
|
• epidermis of weaning-aged mice dosed with doxycycline displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
|
|
|
• weaning-aged mice dosed with doxycycline develop dermatitis on scalp and shoulders, as well as ventral surface, within 3-4 weeks; dermatitis extends caudally with time
|
cellular
|
|
• treatment with doxycycline induces keratinocyte apoptosis
|
|
|
• cell proliferation in hyperplastic dermis of doxycycline-treated animals is elevated
|
|
|
• when adult mice undergo depilation and receive doxycycline treatment, cell proliferation is significantly reduced compared to mice which receive no doxycycline or single-transgenic controls
|
integument
|
|
• treatment with doxycycline induces keratinocyte apoptosis
|
|
|
• epidermis of weaning-aged mice dosed with doxycycline displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
|
|
|
• weaning-aged mice dosed with doxycycline develop dermatitis on scalp and shoulders, as well as ventral surface, within 3-4 weeks; dermatitis extends caudally with time
|
|
|
• weaning-aged mice dosed with doxycycline display progressive hair loss within 3-4 weeks
|
|
|
• in weaning-aged mice dosed with doxycycline, many hair follicles appear hyperplastic with abnormal morphologies
• in animals treated with doxycycline, nearly all hair follicles have proliferating cells in the outer root sheath particularly in the infundibular region
|
|
|
• hair follicle density is significantly reduced in weaning-aged mice dosed with doxycycline
|
|
|
• treatment of animals with doxycycline causes keratinocytes to undergo growth arrest
|
|
|
• increased cellularity is observed in weaning-aged mice dosed with doxycycline
|
|
|
• significant thickening is observed in weaning-aged mice dosed with doxycycline
|
|
|
• weaning-aged mice dosed with doxycycline develop hyperkeratosis within 3-4 weeks
|
|
|
• epidermis of affected mice (weanlings treated with doxycycline) becomes acanthotic
|
|
|
• epidermis of affected mice (weanlings treated with doxycycline) exhibits hyperplasia
|
Analysis Tools